Cubist Systematic Strategies LLC Has $3.18 Million Holdings in Qiagen (NYSE:QGEN)

Cubist Systematic Strategies LLC decreased its stake in Qiagen (NYSE:QGEN - Free Report) by 50.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,428 shares of the company's stock after selling 73,960 shares during the period. Cubist Systematic Strategies LLC's holdings in Qiagen were worth $3,181,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Cetera Investment Advisers grew its holdings in shares of Qiagen by 14.4% in the 4th quarter. Cetera Investment Advisers now owns 11,297 shares of the company's stock valued at $505,000 after acquiring an additional 1,418 shares in the last quarter. Bridgefront Capital LLC bought a new position in shares of Qiagen in the 4th quarter valued at about $281,000. BLI Banque de Luxembourg Investments bought a new position in shares of Qiagen in the 4th quarter valued at about $564,000. Ameriprise Financial Inc. grew its holdings in shares of Qiagen by 66.3% in the 4th quarter. Ameriprise Financial Inc. now owns 63,026 shares of the company's stock valued at $2,807,000 after acquiring an additional 25,134 shares in the last quarter. Finally, Freestone Grove Partners LP bought a new position in shares of Qiagen in the 4th quarter valued at about $23,584,000. Institutional investors own 70.00% of the company's stock.

Analyst Upgrades and Downgrades

QGEN has been the subject of a number of research analyst reports. Baird R W cut Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. UBS Group reduced their price target on Qiagen from $50.00 to $48.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Redburn Atlantic cut Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Robert W. Baird boosted their price objective on Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Finally, StockNews.com upgraded Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday. Seven equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $48.42.

Qiagen Price Performance

Shares of NYSE QGEN traded up $0.27 during midday trading on Friday, reaching $42.51. The company's stock had a trading volume of 291,298 shares, compared to its average volume of 1,143,413. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30. The business's 50 day moving average price is $40.90 and its two-hundred day moving average price is $41.79. The company has a market cap of $9.45 billion, a P/E ratio of 118.47, a P/E/G ratio of 2.39 and a beta of 0.67.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.50 by $0.05. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The business had revenue of $483.46 million during the quarter, compared to the consensus estimate of $465.66 million. During the same period in the previous year, the business earned $0.44 earnings per share. The company's revenue was up 5.2% on a year-over-year basis. On average, analysts forecast that Qiagen will post 2.26 EPS for the current fiscal year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.